Immunome Corp Overviewimmunome.com/wp-content/...Overview-Feb2016.pdf · Immunome Overview •A biotechnology company leveraging tumor immunology to develop cancer therapeutics •Experienced

CORPORATE OVERVIEW February 2016

USING THE HUMAN IMMUNE SYSTEM TO CHANGE THE

PARADIGM OF CANCER TREATMENT

Immunome Overview

• A biotechnology company leveraging tumor immunology to develop cancer therapeutics

• Experienced management and drug development team

• Pipeline of antigen-antibody pairs Fully human antibodies engineered for safe and robust anti-tumor

activity

Uniquely enables ADC and CAR T therapeutic strategies

• Proprietary platforms RealMab™

• Isolates antibodies from privileged patients (super responders) raised against their own tumors

• Cancer neo-antigens recognized by these antibodies

ScreenMab™ • Patient antibodies screened for desired functional profiles

• Recent $8.5M Series A Rapidly building out the team and advancing products to the clinic

2

Jane H. Hollingsworth

Executive Chair and

Interim CEO

• Founder and Former CEO, NuPathe (PATH) – sold to TEVA for $300 million

• Founder and Former EVP, Auxilium (AUXL) – sold to ENDP for $2.6 billion

• Former VP, Secretary & General Counsel of IBAH (IBAH)

Joan Lau, PhD

Chief Operating Officer

• Former CEO, Azelon

• Former CEO, Locus

• Former R&D Leader and Business Development Executive, Merck

Scott Dessain, MD, PhD

Chief Scientific Officer

and Founder

• Associate Professor, Lankenau Institute for Medical Research

• Former Instructor, Massachusetts General Hospital

• Post-doctoral training under Dr. Robert Weinberg, Whitehead Institute

Joel Sussman

Chief Financial Officer

• Serves as part time CFO of PhaseBio and Galera Therapeutics

• Former CFO of Adolor, BioRexis, Tetralogic and NuPathe

• Certified Public Accountant

Shawn D. Bridy

VP & Head of Business

Development

• Former Business Development Director, Elan Pharmaceuticals (ELN)

• Former Executive at GlaxoSmithKline, Global Commercial Strategy, Oncology

• Former VP of Strategy and Business Development, BTG plc (LSE:BGC)

Experienced Management Team

Scientific and Strategic Advisors

4

Brian Daniels, MD • Venture Partner of 5AM Venture Management

• Senior Advisor, Boston Consulting Group

• Former SVP of Global Development and Medical Affairs, R&D of Bristol-Myers Squibb

Michael J. Morin, PhD • Former VP Immunology, Antibacterials and Cancer Discovery, Pfizer

• Former Chief Scientific Officer, Onkaido Therapeutics

• Advisor to venture-backed and public cancer therapeutics companies

Louis M. Weiner, MD • Professor & Director, Lombardi Cancer Center of Georgetown University, Chair, Dept

of Oncology

• Founder, Jounce Therapeutics

• Former Chair of Medical Oncology & VP Translational Research at Fox Chase Cancer

Center

Donald Drakeman, PhD • Venture Partner, Advent Venture Partners and Fellow of Health Management,

University of Cambridge

• Founder and former CEO, Medarex

• Founder Genmab

Shawn Langer, MD

• BMHS Investments, Operating Partner

• Former Senior Partner, McKinsey & Company; leader healthcare private equity

practice

5

Rapid Discovery of Antigen-Antibody Pairs

Select Cancer Patients

Extract Primary B-Cells

from Sentinel Lymph

Nodes

Create B Cell Fusions Using

Proprietary Human Hybridoma

Technology (RealMab)

+

Initiate Multiplex Functional Screening Process

(ScreenMab)

Produce Libraries of Thousands of

Antibodies Enriched for Tumor Antigen

Binding

Generate Stable

Human Hybridomas in 22 Days

= Telomerase and

Interleukin-6 Stabilize

High-level Human

Antibody Expression

Hybridomas Express

Original, Fully Human

Antibodies at High

Fidelity

Results in the Most Meaningful

Cancer Specific Antigen Antibody

Pairs in 6 Months

Confirm and Adapt to Suitable

Format (ADC, CAR T, NK or Bi-

Specific)

B-cells Sourced from

Super-Responders to

Checkpoint Inhibitor

Therapies

Robust Discovery Stage Pipeline Targeting Novel Antigens

6

Antibody Antigen Profile Targeted Indication Suitable Format

IMM-002 • Known cancer target involved in cell

invasion

• Cancer cells (vs normal) express the antigen

on the outer plasma membrane

Breast, Lung T Cell Engager

IMM-003 • Internalizing Breast, Lung ADC

IMM-005 • Expression in tumor (versus normal) human

tissue

• Post translational modification

Breast, Colon T Cell Engager

IMM-009 • Activity in triple negative BRCA cell lines

• Internalizing

Breast, Lung ADC

IMM-010 • Internalizing Breast, Lung ADC

IMM-045 • IgM post germinal center

• CDC activity

Major Solid Tumors T Cell Engager

Antigens identified suggest

diverse MOA

Leads suitable for state-of-the-art

approaches to targeted therapeutics

IMM-002: The First Recognition of this Antigen Present on the

Outer Plasma Membrane

7

• A known cancer target involved in cell

invasion

• Its location on the outer cell membrane

was previously unknown

• Antigen confirmed via mutational

analyses

• In normal cells, it is only intracellular

• Extracellular expression is induced by

the genetic changes converting a

normal human cell into a cancer cell

• The IMM-002 antigen does not

internalize

Antibody IMM-002

Antigen Profile

(Features)

• Cancer (vs normal) cell express the

antigen on the outer plasma

membrane

• Known cancer target involved in

cell invasion

Expression Antigen is in every cell, but over-

expressed in many tumor types

Targeted Indication Breast, lung

Suitable Format ADCC, CAR T

IMM-002 Antigen Is Expressed on Diverse Tumor Types

8

A549 Lung cancer

MDA MB 231 claudin low

breast cancer

MCF7

Breast luminal A

(ER+PR+)

SK-BR-3

Breast HER2

Antibody IMM-002

Antigen Profile

(Features)

• Cancer (vs normal) cell express the

antigen on the outer plasma

membrane

• Known cancer target involved in

cell invasion

Expression Antigen is in every cell, but over-

expressed in many tumor types

Targeted Indication Breast, lung

Suitable Format ADCC, CAR T

• IMM-002 antigen expressed by all

three breast cancer types as well as

lung adenocarcinoma

IMM-002 Antigen Mutants Fail to Reach the Outer Plasma

Membrane

9

• Antigen present in cells

• Outer plasma

membrane expression

only in cancer cells

• Loss of function

mutation prevents

translocation to the

outer plasma

membrane

Multiple Antibody Leads Internalize, Suggesting Potential as

ADCs

Red signals denote endosomes that have internalized the mAbs.

Nuclei are stained blue. Extracellular signals are artifacts of cell fixation.

Isotype

control

2°AB

only

10

Antigen-Antibody Identification Companies

Function Based

Repertoire

Screening

11

Computational

Repertoire

Screening

Human Immune Response

Informed Target Discovery

Non-Human

Target Discovery

Novel Antigen-Antibody Companies and Leads Are in High

Demand

12

Juno Therapeutics Adds

Next-Generation Single Cell

Sequencing Capabilities

Through Acquisition of

AbVitro – Jan 2016

$130M Acquisition

“AbVitro’s technology allows for

the identification of fully-human,

natively paired …binders

directly from cancer patients.

This capability …enables the

generation of binders that

recognize known targets as well

as the discovery of novel cancer

antigen targets…to provide a

better understanding of the

natural immune response to

cancer...Payment of

Approximately $78 M and

1,289,193 Shares of Stock.”

MD Anderson Cancer Center

and Theraclone Launch New

Immuno-Oncology Company

OncoResponse with $10

Million Series A – Oct 2015

$9.5M Series A

“OncoResponse closed a Series

A financing round worth $9.5

million…the startup will

utilize Theraclone’s I-STAR

platform…this technology

screens antibodies produced

by the human body in order to

identify those that have

particular sensitivity and

reactivity that might be useful

for cancer drugs.”

Atreca, Inc., Completes

Oversubscribed $56 Million

Series A Funding to

Advance Pipeline of Novel

Cancer – Nov 2015

$56M Series A

Atreca, Inc., a company focused

on developing novel therapeutics

based on a deep understanding of

the human immune response,

announced today the completion

of its Series A funding with a total

investment of $56 million…A

patient’s own anti-cancer

immune response is the key

phenomenon driving the

exciting clinical outcomes seen

with checkpoint inhibitors and

other immune activators.”

bluebird bio and Five Prime

Therapeutics Enter into

License Agreement for

Novel Antibodies to Develop

Chimeric Antigen Receptor

T Cell Therapy – May 2015

$130M Potential per Product

“Five Prime will provide bluebird

bio exclusive rights to its novel

human antibodies to the

target…upfront payment and

subsequent milestone payments

to Five Prime, which together

could total over $130 million per

licensed product if certain

development, regulatory, and

commercial milestones are

achieved.”

Recent Antigen-Antibody Deals

Invention Claim(s) Status

Fusion partner cell lines and uses

thereof

A fusion partner cell with hTERT

and mIL-6

US Patent 7,491,530

• Issued 2009

A novel fusion partner cell line for the

creation of hybrid cells expressing

human antibodies

Improved fusion partner US Patent 8,557,575

• Issued 2013

Method of making hybrid cells that

express useful antibodies

Selection and pretreatment of B

cells

US Patent 8,999,707

• Issued 2015

Issued in Europe

Pending in Japan

Anti-IMM-002 Antigen and uses

thereof

Composition of a molecule

binding to cancer specific

expression of TARGET1

US Application 14/961,492

PCT/US2015/064285

IMM-005 Antigen binding molecules

and uses thereof

mAb and antibody fragments

binding to TARGET2

Patent Application Filed

Patent applications are being filed on novel antigen-antibody pairs

as they are discovered and validated

13

Expanding Patent Portfolio

Immunome Overview

• A biotechnology company leveraging tumor immunology to develop cancer therapeutics

• Experienced management and drug development team

• Pipeline of antigen-antibody pairs Fully human antibodies engineered for safe and robust anti-tumor

activity

Uniquely enables ADC and CAR T therapeutic strategies

• Proprietary platforms RealMab™

• Isolates antibodies from privileged patients (super responders) raised against their own tumors.

• Cancer neo-antigens recognized by these antibodies

ScreenMab™ • Patient antibodies screened for desired functional profiles

• Recent $8.5M Series A Rapidly building out the team and advancing products to the clinic

14

Contact Us

15

215-239-6274

[email protected]

www.immunome.com

Immunome, Inc.

Investors

Jane H. Hollingsworth, Executive Chair &

Interim CEO

[email protected]

Partnering & Collaboration

Shawn D. Bridy, VP & Head of Business

Development

[email protected]